Viking Therapeutics Inc
Biotechnology
Viking Therapeutics Inc (VKTX) Stock News
The latest VKTX headlines and market coverage — 2 recent stories, updated throughout the day.
- Zacks Investment Research·Neutral
Is It Worth Investing in Viking Therapeutics (VKTX) Based on Wall Street's Bullish Views?
While Wall Street analysts give Viking Therapeutics (VKTX) a strong buy recommendation with an average brokerage rating of 1.30, the article cautions that brokerage recommendations often have a positive bias and may not reliably predict stock performance. The Zacks Rank system, which relies on earnings estimate revisions, rates VKTX as a Hold (#3), suggesting investors should be cautious despite the bullish analyst sentiment.
- Zacks Investment Research·
Viking Therapeutics, Inc. (VKTX) Outperforms Broader Market: What You Need to Know
Viking Therapeutics (VKTX) gained 1.43% in the latest session, outperforming the S&P 500's 1.06% gain. However, the stock has depreciated 0.03% over the past month, underperforming the Medical sector's 5.75% gain. The company is expected to report an EPS of -$1 (down 23.46% YoY) with full-year consensus estimates of -$4.47 EPS and $0 million revenue. VKTX holds a Zacks Rank #3 (Hold) rating, while its industry (Medical - Biomedical and Genetics) ranks in the bottom 34% of all industries.